Introduction
The transforming growth factor-beta (TGF-b) family of cytokines, including TGF-bs and bone morphogenetic proteins (BMPs), exerts diverse functions in many types of cells and tissues. Cell proliferation, differentiation, apoptosis, migration and extracellular matrix remodeling can all be regulated by TGF-b, although the biological outcomes often vary in different cellular contexts (Massague´, 2000; . During tumor progression, TGF-b has a dual function such that in the early phase of tumorigenesis, TGF-b functions as a tumor suppressor by inhibiting abnormal cell proliferation, whereas in advanced tumors, TGF-b often stimulates tumor cell invasion and metastasis, thereby acting as a tumor promoter (Bierie and Moses, 2006) .
Cells perceive TGF-b signals through cell-surface proteins termed type I and type II TGF-b receptors (TbRI and TbRII), both being serine/threonine kinases. Upon TGF-b ligand binding, TbRI and TbRII form a heterotetrameric complex, within which TbRI is phosphorylated and activated by TbRII. In the canonical TGF-b pathway, TbRI in turn directly phosphorylates and activates downstream transcription factors called receptor-regulated Smad proteins (R-Smads). Two essential R-Smads, Smad2 and Smad3, specifically transduce TGF-b signals, and both Smads contain an SXS motif at their extreme C termini that serves as the phosphorylation site for TbRI. Activated Smad2 and Smad3 then interact with the common partner Smad, Smad4, and this heteromeric Smad complex becomes enriched in the nucleus, where the Smad proteins join with other transcription co-factors to regulate the expression of TGF-b target genes (reviewed by Massague´(2000) ; Shi and Massague´(2003) ; Massague´et al. (2005) ).
Highly homologous in protein sequence and structure, Smad2 and Smad3 are both organized into an N-terminal MH1 domain and a C-terminal MH2 domain connected by a linker region. Numerous proteins have been shown to directly bind specific regions of the MH1 and MH2 domains and confer diverse regulations of Smad functions. In addition, the MH2 domain is critical for the nucleocytoplasmic shuttling of Smad2 and Smad3, and the MH1 domain of Smad3 (but not Smad2) contains a hairpin structure that is responsible for DNA binding (reviewed by Heldin et al. (1997) ; Massague´(2000) ; Shi and Massague( 2003) ). Notably, Smad2 has a unique 30-amino-acid sequence in its MH1 domain (Dennler et al., 1999; Yagi et al., 1999) , resulting in the inability of Smad2 to directly bind DNA and many other proteins (Shi et al., 1998; Jayaraman and Massague´, 2000; Guo et al., 2008) . Owing to this and other differences, Smad2 and Smad3 have overlapping but sometimes distinct functions in gene regulations (Piek et al., 2001; Kretschmer et al., 2003; Dunn et al., 2005 ; reviewed by Weinstein et al. (2000) and Roberts et al.( 2006) ).
TbRI-mediated C-terminal phosphorylation is a key step in the activation and propagation of Smad signaling, and its level reflects the overall TGF-b activity in cultured cells and in tissue samples. In vitro experiments have shown that activated Smad2 and Smad3 (P-Smad2/Smad3) can be detected with phosphospecific antibodies soon after TGF-b stimulation (5-10 min), and the level of P-Smad2/Smad3 peaks at approximately 45-60 min after treatment and then gradually declines (Lo and Massague´, 1999; Fukuchi et al., 2001; Inman et al., 2002; Lin et al., 2006) . Research in the last decade has indicated two separate mechanisms accounting for the reduction of P-Smad2/ Smad3 in the presence of persistent TGF-b stimulation (reviewed by Heldin and ten Dijke (1999) and Schilling et al. (2006) ). The majority of activated Smad2 and Smad3 is dephosphorylated in the nucleus by a particular phosphatase, PPM1A (Lin et al., 2006) . As a result, the deactivated Smads are recycled back to the cytoplasm for the next round of activation if the extracellular stimulus remains present (Inman et al., 2002; Xu et al., 2002; Reguly and Wrana, 2003; Schmierer and Hill, 2005; Lin et al., 2006) . Besides the reversible tail phosphorylation of Smad2 and Smad3, TGF-b signaling can also be irreversibly terminated by destruction of the activated Smad proteins through the ubiquitin-dependent proteasomal pathway (Lo and Massague´, 1999; Lin et al., 2000; Fukuchi et al., 2001 and reviewed by Izzi and Attisano (2006) ). Polyubiquitination of activated Smad2 (mediated by the E2 enzymes UbcH5b/c) and Smad3 (mediated by the F-Box protein b-TrCP/Fbw1a) is thought to occur in the nucleus, and the ubiquitination site is probably located in the MH2 domain of these proteins (Lo and Massague´, 1999; Fukuchi et al., 2001) .
Casein kinase 1 (CKI) is a family of evolutionarily conserved serine/threonine kinases including seven known members in vertebrates (CKIa, . The CKIs contain a typical kinase domain followed by a C-terminal tail region, which has been implicated in the regulation of CKI localization, substrate selectivity and kinase activity. A myriad of proteins have been found to be phosphorylated by CKIs, which are involved in a wide range of cellular functions including vesicular trafficking, DNA damage repair, cell cycle progression, cytokinesis and circadian rhythms (reviewed by Gross and Anderson (1998) ; Vielhaber and Virshup (2001) ; Knippschild et al. (2005) ). Moreover, it is well established that CKI family members (-a, -d/e and -g ) modulate the activities of major signaling pathways (for example, Wnt and Shh) through several different mechanisms (Peters et al., 1999; Liu et al., 2002; Price and Kalderon, 2002; Davidson et al., 2005; Zeng et al., 2005 and reviewed by Price (2006) ).
In our early efforts to identify potential Smad3 regulators, a number of cDNAs were isolated from a yeast two-hybrid screen using Smad3 as bait. Several of the encoded proteins, such as HDAC1, JunB, WWP1 and PIAS-1, have been confirmed by us and others to directly bind Smad3 and regulate TGF-b activity (Liberati et al., 1999 (Liberati et al., , 2001 Komuro et al., 2004; Long et al., 2004 and our unpublished data) . Interestingly, three separate coding sequences recovered from the screen correspond to human CKIg2 (CSNK1G2, NM_001319). One of these clones (no. 137) encodes the final 188 amino acids of CKIg2 (aa 228-415), which was termed CKIg2DN and encompasses the last third of the kinase domain and the entire tail region. CKIg2, together with two other members, CKIg1 and CKIg3, belongs to the CKIg subfamily of CKIs (Zhai et al., 1995; Kitabayashi et al., 1997) . Although the function of CKIg in TGF-b signaling had been elusive, our parallel work showed that CKIa, -d and -e are bona fide Smad3-binding proteins in vivo that regulate TGF-b signal transduction (Waddell et al., 2004 and our unpublished data) . These findings prompted us to investigate the function of CKIg2 in the regulation of TGF-b/Smad3 activity.
Here we demonstrate that CKIg2 selectively interacts with Smad3 in mammalian cells and inhibits Smad3-mediated TGF-b activity. CKIg2 directly phosphorylates Smad3 at Ser418, leading to the increased ubiquitination and proteasomal degradation of activated Smad3 following TGF-b treatment. Therefore, ubiquitination of ligand-activated Smad3 is a regulated event, and CKIg2 is the first kinase known to control the signaling duration of Smad3 in this manner.
Results

CKIg2 selectively binds Smad3
The physical interaction between CKIg2 and Smad3 was first confirmed by in vitro binding assays. GSTCKIg2DN was incubated with in vitro translated 35 S-labeled Smad3, and the direct interaction between the two proteins was readily detectable following glutathione S-transferase (GST) pull-down assay (data not shown). In addition, bacterially purified fulllength CKIg2 also directly bound GST-Smad3 but not GST alone (Supplementary Figure S1A) . We then expressed epitope-tagged CKIg2 and Smad3 in 293T cells to examine their in vivo interaction and found that both CKIg2(WT) and the kinase-deficient mutant, CKIg2(KD), co-precipitated with Smad3 ( Figure 1a ). Further analysis showed that the Smad3-MH2 domain is sufficient to mediate CKIg2 binding, whereas a partial deletion of this domain abolished Smad3-CKIg2 interaction (Supplementary Figure S1A and B) . In contrast to Smad3, overexpressed Smad1 (mediating BMP signals), Smad2 and Smad4 failed to co-immunoprecipitate with CKIg2 ( Figure 1b ). This selective interaction was also seen with endogenous proteins from HaCaT CKIc2 inhibits Smad3 activity X Guo et al cell lysates, as only Smad3 was detected from the antiCKIg2 precipitates ( Figure 1c ). Next, we examined whether the Smad3-CKIg2 interaction is affected by TGF-b treatment, which reduces/disrupts the binding between Smad3 and some other CKI members (for example, CKIe and -a; Waddell et al. (2004) and our unpublished data). Interestingly, unlike the other CKIs, CKIg2 remained bound to Smad3 in the presence of TGF-b (Figures 1c and d) , which is consistent with its ability to bind the Smad3(2SD) mutant that mimics receptor-phosphorylated Smad3 (Figure 1a ). In fact, TGF-b slightly increased the Smad3-CKIg2 interaction. These data suggest that CKIg2 may have a unique function in regulating activated Smad3.
CKIg2 inhibits Smad3 transcriptional activity
To explore the functional role of CKIg2 in the TGF-b/ Smad3 pathway, we first determined by reverse transcription PCR that CKIg2 is expressed in several human cell lines commonly used for TGF-b studies, such as HaCaT (human keratinocyte), HepG2 (hepatocellular carcinoma) and U2OS (osteosarcoma) cells (data not shown). CKIg2 also appeared to be the major, if not the only, member of the CKIg subfamily being expressed in those cells. Next, we generated two short hairpin-type RNA constructs against independent coding regions of CKIg2 (designated as R1 and R2) that effectively downregulated CKIg2 protein (Figures 2a and e) . When co-expressed with a Smad3-specific SBE-Lux luciferase reporter in HepG2 cells, both short hairpin-type RNAs caused a significant increase of Smad3 transcriptional activity but only in the presence of TGF-b (Figure 2b ). CKIg2 knockdown did not alter the expression of the MBE-Lux reporter (a mutant control for SBE, Figure 2c ), nor did it affect the Smad2-specific ARE-Luc activity (Figure 2d ), indicating that CKIg2 specifically inhibits Smad3-mediated transcription.
To further gauge this inhibitory effect of CKIg2 on Smad3 signaling, we engineered HaCaT cells that stably overexpress wild-type (WT) or kinase-dead (KD) CKIg2, as well as a stable knockdown line (RNAi) (Figures 2e and 4a) . The expression level of CKIg2 in CKIc2 inhibits Smad3 activity X Guo et al these cell lines was confirmed by immunoblotting using a rabbit polyclonal antibody (CKIg2-2026) generated in our laboratory. In a luciferase assay using the 3TP-Luc reporter, the overexpression of WT CKIg2 almost completely abolished TGF-b-induced activity, whereas this inhibition was fully reversed by transient knockdown of the overexpressed CKIg2 to the endogenous level ( Figure 2e , lanes 1-3). In contrast, the KD mutant of CKIg2 had no effect on the reporter at all, and stable downregulation of CKIg2 led to an increased reporter activity (Figure 2e, lanes 4-5) . Similar results were seen with other reporter constructs such as PAI-1-Luc and p15HD-Lux in the same HaCaT lines (data not shown). These results further demonstrate that CKIg2 negatively regulates TGF-b/Smad3 activity in a kinase-dependent manner.
CKIg2 attenuates TGF-b-induced biological responses
We then investigated whether CKIg2 affects TGF-bregulated biological activity at the cellular level. TGF-b can cause growth arrest in normal epithelial cells and keratinocytes, which is achieved through Smad3-mediated downregulation of the proto-oncogene c-myc and upregulation of cyclin-dependent kinase inhibitors such as p21 and p15 . In HaCaT cells, this antiproliferative effect of TGF-b was severely impaired by CKIg2 overexpression but markedly augmented by CKIg2 RNAi (Figure 3a) . Consistently, the downregulation of the c-myc protein by TGF-b was more prominent in the CKIg2-RNAi cells (decreased by >50% within 1 h of TGF-b treatment) than in control cells, whereas there was barely any reduction in c-myc level in the CKIg2-WT cells after 2 h of treatment ( Figure 3b ). TGF-b-induced expression of p21 was also significantly delayed and weakened in the CKIg2-WT cells, whereas the opposite was seen in the CKIg2-RNAi cells (Figures 3c and d) . In addition to cytostasis, TGFb-stimulated cell migration was also blocked in HaCaT cells overexpressing CKIg2 but enhanced in the knockdown cells (Figure 3e ). Note that in untreated cells, the varied levels of CKIg2 did not produce a difference in cell proliferation or motility at the basal level. Therefore, the inhibitory function of CKIg2 in the TGF-b/ Smad3 pathway appeared to be ligand dependent. We also employed transient transfection to confirm the negative function of CKIg2 in TGF-b responses. Mouse embryonic fibroblasts expressing identical amount of WT or KD CKIg2 were stimulated with TGF-b, and the expression of endogenous Smad3 target genes such as integrin a5, JunB and CTGF (connective tissue growth factor) was measured. Overexpression of CKIg2(WT), but not CKIg2(KD), considerably attenuated the induction of those genes and also downregulated Smad3 in the presence of TGF-b (Figure 3f ). These results again indicate that CKIg2 inhibits TGF-b signaling, likely through the regulation of activated Smad3.
CKIg2 promotes proteasomal degradation of activated Smad3
We then probed for the mechanism by which CKIg2 regulates the TGF-b/Smad3 pathway. First, CKIg2 did not affect the protein levels of Smad2, -3 or -4 in unstimulated HaCaT cells (Figure 4a ). Second, both Smad2 and Smad3 were properly activated by shortterm TGF-b treatment (30-60 min) regardless of CKIg2 overexpression, suggesting that CKIg2 does not interfere with TGF-b receptor activity (Figure 4b) . However, when the time course was extended to 4 or 6 h, the levels of P-Smad3 (activated) and total Smad3 became much lower in CKIg2-overexpressing cells than in control cells (Figures 4c, d , e and Supplementary Figure S2 ). This effect of CKIg2 was unlikely because of an increased phosphatase activity against P-Smad3, as P-Smad2, which is dephosphorylated by the same phosphatase PPM1A (Lin et al., 2006) , was unaffected by CKIg2 (Figures 4d, e and Supplementary Figure S2) . Instead, the reduction of P-Smad3 and total Smad3 caused by CKIg2 overexpression could be rescued by pretreating the cells with the proteasome inhibitor, MG-132 ( Figure 4c and Supplementary Figure S2 ). This latter result suggests that CKIg2 downregulates P-Smad3 by promoting its degradation, a notion consistent with the gradual loss of Smad3 protein after prolonged TGF-b stimulation as seen in Figure 3f . Furthermore, TGF-bactivated endogenous Smad3 was more strongly polyubiquitinated in HaCaT(CKIg2-WT) cells than in control or CKIg2(KD) cells, whereas this ligandinduced Smad3 ubiquitination was almost completely suppressed by CKIg2 RNAi (Figure 4f) . Lastly, the binding between endogenous Smad3 and the F-box protein b-TrCP was enhanced by CKIg2 following TGF-b treatment (Figure 4g ). All together, these data demonstrate that CKIg2 accelerates the proteasomal degradation of activated Smad3, thereby shortening its signaling duration and inhibiting TGF-b activity.
CKIg2 directly phosphorylates Smad3
As CKIg2 inhibits Smad3 activity in a kinase-dependent manner, we examined whether Smad3 is a direct substrate of CKIg2. In vitro, CKIg2 strongly phosphorylated purified GST-Smad3 (Figure 5a ). Mass spectrometry analysis showed that CKIg2 phosphorylates the MH2 domain of Smad3 at a single residue, Ser418 (recovered in peptide VLTQMGSPpSIR, see Supplementary Data for details). Indeed, purified Smad3-MH2 domain alone (termed GST-S3C) could be directly phosphorylated by CKIg2, and the phosphorylation was blocked by mutating Ser418 to alanine (S418A) (Figure 5b ). In line with this, CKIg2 overexpression significantly decreased the protein level/ stability of Flag-S3C, whereas the MH1 þ Linker region of Smad3 (Flag-S3NL) was unaffected (Figure 5c ).
Ser418 phosphorylation controls Smad3 stability/activity
To understand the functional role of Ser418 phosphorylation by CKIg2 in cells, we compared the stability and activity of Smad3(WT), Smad3(S418A, phosphodeficient) and Smad3(S418D, phosphomimetic). Ser418 mutations did not affect Smad3 expression in untreated cells or the early-phase activation of Smad3 by shortterm (0.5-1 h) TGF-b treatment (Figures 6a and b) .
CKIc2 inhibits Smad3 activity X Guo et al
However, after prolonged TGF-b stimulation, the S418D mutant showed a much lower level of C-terminal phosphorylation than Smad3(WT) (Figure 6a, left) , consistent with our postulation that CKIg2-mediated phosphorylation downregulates the activated form of Smad3. Owing to the rapid removal of activated Smad3(S418D), TGF-b-induced upregulation of Smad3 target genes such as integrin a5 and CTGF was greatly compromised in cells expressing this mutant (Figure 6a , left). It is noteworthy that pretreating cells with MG-132 effectively stabilized C-terminally phosphorylated Smad3(S418D) and fully restored its activity (Figure 6a, right) . This result indicates that S418 phosphorylation does not perturb the intrinsic transactivating CKIc2 inhibits Smad3 activity X Guo et al ability of Smad3 but attenuates Smad3 activity by lowering its protein stability in the presence of TGF-b. Indeed, the S418D mutation or CKIg2 overexpression did not affect the DNA-binding ability of Smad3 or its affinity to Smad4 in the presence of MG-132 (Supplementary Figure S4 ). On the other hand, the phosphodeficient S418A mutant was more resistant to CKIg2 overexpression than WT Smad3 (Figure 6b ), further supporting that Ser418 is a critical site for CKIg2 to inhibit Smad3 function. We also expressed these Smad3 variants in SMAD3 À/À mouse embryonic fibroblasts and HepG2 cells to measure the SBE-Lux activity and growth inhibition, respectively (Figures 6c and d) . In both the assays, the Smad3 mutants exhibited almost identical basal activity as WT Smad3 in the absence of TGF-b. However, upon activation, Smad3(S418A) was more potent, whereas Smad3(S418D) was much weaker, than Smad3(WT) in activating downstream responses (Figures 6c and d) . Taken together, we conclude that CKIg2 inhibits TGF-b signaling by destabilizing the activated form of Smad3 through direct phosphorylation of Ser418.
Discussion
One striking feature of TGF-b/Smad signaling is the combination of versatility and accuracy, which is ensured by a plethora of regulatory proteins that control every step of the TGF-b pathway. Many Smad3-interacting proteins are of yet unknown identities and functions. In this study, we demonstrated that CKIg2 is a novel Smad3-binding protein that targets activated Smad3 to ubiquitination and degradation, thus revealing another mechanism for the regulation of TGF-b signaling.
Most Smad proteins can be polyubiquitinated in either a ligand-dependent or a ligand-independent manner (reviewed by Izzi and Attisano (2006) ). As for R-Smads, ubiquitination and degradation at the steady state (without ligand stimulation) lead to lowered CKIc2 inhibits Smad3 activity X Guo et al ubiquitination. However, our knowledge about the molecular events that precede and trigger those ubiquitination reactions remains incomplete. Very recently, we reported that ubiquitination and degradation of nonactivated Smad3 is synergistically regulated by the scaffolding protein Axin and its associated kinase, GSK3-b (Guo et al., 2008 ; Figure 7 ). Our unpublished results also indicate a requirement for CKIa, a CKI family member, in the basal degradation of Smad3. In this study, we have demonstrated that ubiquitination and degradation of TGF-b-activated Smad3 is controlled by a different CKI, CKIg2. Therefore, two CKI family members can induce Smad3 ubiquitination and negatively regulate TGF-b activity but through different mechanisms (Figure 7) . TGF-b stimulates the translocation of Smad2 and Smad3 into the nucleus, where they can be assembled into protein complexes for transcriptional regulation, or be dephosphorylated and exported to the cytoplasm, or undergo polyubiquitination (Shi and Massague´, 2003) . Therefore, when these Smads need to be eliminated as a way to swiftly and irreversibly turn off TGF-b responses, additional signals must be given to specifically direct them down the degradation pathway. In regard to Smad3, one of such signals, as we demonstrated in this study, is its phosphorylation by CKIg2 at Ser418. This extra step of regulation determines whether an activated Smad3 molecule is to be labeled for destruction, thereby representing an important mechanism to ensure the proper signaling duration of TGF-b.
One interesting question, however, is where exactly in the cell CKIg2 phosphorylates Smad3. Our fluorescence microscopy and biochemical fractionation analyses showed that CKIg2 is localized in the cytoplasm, in the nucleus and at the plasma membrane (see Supplementary Data for details). Although the plasma membrane association appears to be critical for CKIg2 to regulate Wnt/b-catenin signaling (Davidson et al., 2005) , it is not required for Smad3 regulation. On the other hand, different CKIg2 mutants that are either unable to enter the nucleus or highly enriched in the nucleus all inhibited Smad3 activity and reduced P-Smad3 stability in a similar manner as WT CKIg2 (Supplementary Figures S5 and S6) . Therefore, Smad3 may be phosphorylated by CKIg2 in the cytoplasm or in the nucleus or both, and this phosphorylation may occur independently of TGF-b stimulation in view of the constitutive binding between CKIg2 and Smad3. However, CKIg2 does not affect the steady-state level of Smad3, and no difference was seen in the protein stability or activity of the Smad3 Ser418 mutants in untreated cells (Figures 4 and 6) . The inhibitory effect of CKIg2 is manifested only when Smad3 is activated (Figures 2-4 ). These observations strongly support the notion that Smad3 regulation by CKIg2 is dependent on TGF-b, which is necessary to place Smad3 in the right environment (that is, the nucleus) and in an optimal CKIc2 inhibits Smad3 activity X Guo et al conformation such that the CKIg2-mediated phosphorylation can be recognized by the appropriate ubiquitination machinery ( Figure 4G and Supplementary Figure S4C ). CKIg2 phosphorylates Smad3 at serine 418, and Ser418 mutants exhibit altered protein stability, activity and sensitivity to CKIg2 following TGF-b stimulation (Figures 5 and 6 ). Ser418 is conserved in Smad3 of human, mouse, rat and frog origins. Interestingly, close to this site is a lysine residue (Lys409) that is also evolutionarily conserved. Among the four lysine residues present in the Smad3-MH2 domain, only the K409R mutation leads to an increase in TGF-b-induced Smad3 activity (Imoto et al., 2005) . This fact raises the tempting possibility that Lys409 might be the ubiquitination site of activated Smad3, as b-TrCP-mediated polyubiquitination is thought to occur in the MH2 domain (Fukuchi et al., 2001) . It would be even more interesting to determine whether Ser418 phosphorylation by CKIg2 is necessary and/or sufficient to trigger Smad3 ubiquitination at Lys409, a hypothesis that we are currently investigating in the laboratory.
It is noteworthy that the BMP Smads (Smad1, -5 and -8) and Smad4 do not possess a site equivalent to Smad3-Ser418, nor do they interact with CKIg2 ( Figure 1) . As a result, CKIg2 does not seem to inhibit BMP signaling (data not shown). Interestingly, although Smad2 contains a residue (Ser460) that corresponds to Smad3-Ser418, it is not associated with or regulated by CKIg2 (Figures 1, 2 and 4) . The inability of Smad2 to bind CKIg2 may result from the unique structure of the Smad2-MH1 domain, as substitution of the MH1 domain of Smad3 with that of Smad2 resulted in a loss of CKIg2 binding to the Smad2/3 chimeric protein (Supplementary Figure S1B) . This is similar to our recent findings that Smad3 and Smad2 are differentially regulated by the Axin/GSK3-b complex because of structural differences of their MH1 domains (Guo et al., 2008) . In addition, Fukuchi et al. (2001) showed that overexpression of b-TrCP cannot induce Smad2 ubiquitination in the nucleus. Therefore, with respect to ubiquitination, Smad2 and Smad3 are differentially regulated. It remains to be seen whether TGF-bdependent Smad2 ubiquitination is also regulated through a similar mechanism as what we hereby demonstrated for Smad3 but by a different kinase.
In mesangial cells, Smad3 is critical in mediating TGF-b-induced fibrosis (reviewed by Wang et al. (2005) ). Long-term TGF-b treatment of these cells causes a significant decrease in the protein level of Smad3 but not Smad2 (Poncelet et al., 2007) , which might well result from the action of CKIg2. Therefore, it would be interesting to determine whether CKIg2 is relevant to the fibrotic responses in the kidney under normal and pathological conditions.
Although the majority of activated Smad3 normally undergoes dephosphorylation and relocates back to the cytoplasm, our study suggests that a significant portion of Smad3 molecules can be shunted toward the proteasomal pathway because of increased CKIg2 activity. Indeed, overexpression of CKIg2 mRNA has been found in several types of cancer (http://www.ncbi.nlm.nih.gov/ UniGene/ESTProfileViewer.cgi?uglist ¼ Hs.651905), in which the cytostatic response to TGF-b is often lost. In addition, CKIg2 not only inhibits TGF-b function but also positively regulates the Wnt pathway (Davidson et al., 2005) . Thus, overexpression of CKIg2 is likely to promote the proliferation of epithelial cells and may be advantageous for tumor growth. Although this notion remains to be firmly established, CKIg2 may act as an oncoprotein and the development of specific CKIg2 inhibitors can be potentially valuable for anticancer therapeutics.
Materials and methods
Plasmids and sequences
Epitope-tagged Smad2 and Smad3 (WT and 2SD) have been used earlier (Guo et al., 2008) . pRK5-Smad1-Flag and pRK5-Smad4-Flag were provided by Rik Derynck (University of California, San Francisco). The cDNA of human CKIg2 in the pMOSBlue vector was a gift of Jun Kusuda and has been described earlier (Kitabayashi et al., 1997) . pSuperRetro-GL2 was described earlier (Guo et al., 2008) . pSuper-and pSuperRetro-CKIg2 were generated according to the manufacturer's protocol (Oligoengine, Seattle, WA, USA). The sequences of primers used for subcloning, mutagenesis and RNAi are described in Supplementary Data.
Cell culture, transfection and retroviral infection
Growth of HaCaT, HepG2, 293T and mouse embryonic fibroblasts has been described (Guo et al., 2008) . HaCaT cells stably overexpressing CKIg2 were generated by transfection of pcDNA3-CKIg2(WT or KD) using LipofectAmine 2000 (Invitrogen Inc., Carlsbad, CA, USA), followed by G418 selection (800 mg/ml, Invitrogen). Retroviral infection of HaCaT cells with pSuperRetro-CKIg2(R1 þ R2) was performed as reported earlier (Guo et al., 2008) . Transient transfection of HaCaT cells was achieved using the FuGene 6 reagent (Roche, Indianapolis, IN, USA). 293T, HepG2 and mouse embryonic fibroblasts were transfected as reported earlier (Guo et al., 2008) .
Antibodies and other reagents
The anti-CKIg2(2026) polyclonal antibody was raised by immunizing a rabbit with GST-CKIg2DN at Duke vivarium according to a standard protocol. Serum from the fourth immunized bleed was centrifuge cleared and used for western blotting of endogenous CKIg2. Integrin a5 polyclonal antibody was provided by Jun-Lin Guan (University of Michigan). Other antibodies used for immunoblotting: Smad3, Smad2 and b-TrCP (Zymed/Invitrogen, Carlsbad, CA, USA); Flag(M2), GFP and g-tubulin (Sigma, St Louis, MO, USA); P-Smad2 and P-Smad3(S423/425) (Cell Signaling, Danvers, MA, USA); actin(C-2), HA(F-7), c-myc(9E10), JunB(C-11), p21(F-5), Smad1/2/3(H-2), CTGF(L-20) and Ubiquitin(P4D1) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The antibodies used for immunoprecipitation were HA(Y-11), CKIg2(C-20) (Santa Cruz Biotechnology) and Smad3 (Zymed). TGF-b1 was obtained from R&D Systems (Minneapolis, MN, USA). SB431542 was purchased from Tocris (Ellisville, MO, USA) and MG-132 from BioMol (Plymouth Meeting, PA, USA).
Western blotting and immunoprecipitation
The protocols for western blotting and immunoprecipitation have been described earlier (Guo et al., 2008) .
Transcriptional reporter assay SBE-Lux and MBE-Lux were gifts from Xin-Hua Feng (Baylor College of Medicine, originally from Bert Vogelstein at Johns Hopkins University). ARE-Luc and FoxH1 were kindly provided by Anita Roberts (National Cancer Institute). 3TP-Luc has been described (Waddell et al., 2004) . Luciferase assays were performed as reported earlier (Guo et al., 2008) . Chemiluminescence was measured by the Victor3 system (PerkinElmer, Waltham, MA, USA).
Cell proliferation and wound-healing assays Cell proliferation and wound-healing assays were performed exactly as described earlier (Guo et al., 2008) .
In vitro kinase assay Flag-CKIg2 overexpressed in 293T cells was immunoprecipitated with an anti-Flag antibody (M2) in radioimmuno precipitation assay buffer (Guo et al., 2008) . The beads were washed twice with radioimmuno precipitation assay buffer, once with high-salt buffer (100 mM Tris-HCl, 500 mM NaCl (pH 7.4)) and once with 1 Â CKI kinase buffer (30mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 7 mM MgC1 2 , 1mM dithiothreitol (pH 7.5)). The immunoprecipitated kinase was then resuspended in 2 Â CKI kinase buffer and incubated with 2 mg of GST fusion proteins, 50 mM unlabeled ATP and 20 mCi [ 32 P]-g-ATP at 371C for 30 min. Reactions were terminated by boiling samples in Laemmli sample buffer for 5 min. Phosphorylated proteins were separated by SDS-polyacrylamide gel electrophoresis and visualized by autoradiography. His-CKIg2 (PV3499) was purchased from Invitrogen (Carlsbad, CA) and used under the same reaction conditions.
